Cargando…
Pathways to Parkinson’s disease: a spotlight on 14-3-3 proteins
14-3-3s represent a family of highly conserved 30 kDa acidic proteins. 14-3-3s recognize and bind specific phospho-sequences on client partners and operate as molecular hubs to regulate their activity, localization, folding, degradation, and protein–protein interactions. 14-3-3s are also associated...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455551/ https://www.ncbi.nlm.nih.gov/pubmed/34548498 http://dx.doi.org/10.1038/s41531-021-00230-6 |
_version_ | 1784570690641330176 |
---|---|
author | Giusto, E. Yacoubian, T. A. Greggio, E. Civiero, L. |
author_facet | Giusto, E. Yacoubian, T. A. Greggio, E. Civiero, L. |
author_sort | Giusto, E. |
collection | PubMed |
description | 14-3-3s represent a family of highly conserved 30 kDa acidic proteins. 14-3-3s recognize and bind specific phospho-sequences on client partners and operate as molecular hubs to regulate their activity, localization, folding, degradation, and protein–protein interactions. 14-3-3s are also associated with the pathogenesis of several diseases, among which Parkinson’s disease (PD). 14-3-3s are found within Lewy bodies (LBs) in PD patients, and their neuroprotective effects have been demonstrated in several animal models of PD. Notably, 14-3-3s interact with some of the major proteins known to be involved in the pathogenesis of PD. Here we first provide a detailed overview of the molecular composition and structural features of 14-3-3s, laying significant emphasis on their peculiar target-binding mechanisms. We then briefly describe the implication of 14-3-3s in the central nervous system and focus on their interaction with LRRK2, α-Synuclein, and Parkin, three of the major players in PD onset and progression. We finally discuss how different types of small molecules may interfere with 14-3-3s interactome, thus representing a valid strategy in the future of drug discovery. |
format | Online Article Text |
id | pubmed-8455551 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-84555512021-10-07 Pathways to Parkinson’s disease: a spotlight on 14-3-3 proteins Giusto, E. Yacoubian, T. A. Greggio, E. Civiero, L. NPJ Parkinsons Dis Review Article 14-3-3s represent a family of highly conserved 30 kDa acidic proteins. 14-3-3s recognize and bind specific phospho-sequences on client partners and operate as molecular hubs to regulate their activity, localization, folding, degradation, and protein–protein interactions. 14-3-3s are also associated with the pathogenesis of several diseases, among which Parkinson’s disease (PD). 14-3-3s are found within Lewy bodies (LBs) in PD patients, and their neuroprotective effects have been demonstrated in several animal models of PD. Notably, 14-3-3s interact with some of the major proteins known to be involved in the pathogenesis of PD. Here we first provide a detailed overview of the molecular composition and structural features of 14-3-3s, laying significant emphasis on their peculiar target-binding mechanisms. We then briefly describe the implication of 14-3-3s in the central nervous system and focus on their interaction with LRRK2, α-Synuclein, and Parkin, three of the major players in PD onset and progression. We finally discuss how different types of small molecules may interfere with 14-3-3s interactome, thus representing a valid strategy in the future of drug discovery. Nature Publishing Group UK 2021-09-21 /pmc/articles/PMC8455551/ /pubmed/34548498 http://dx.doi.org/10.1038/s41531-021-00230-6 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Review Article Giusto, E. Yacoubian, T. A. Greggio, E. Civiero, L. Pathways to Parkinson’s disease: a spotlight on 14-3-3 proteins |
title | Pathways to Parkinson’s disease: a spotlight on 14-3-3 proteins |
title_full | Pathways to Parkinson’s disease: a spotlight on 14-3-3 proteins |
title_fullStr | Pathways to Parkinson’s disease: a spotlight on 14-3-3 proteins |
title_full_unstemmed | Pathways to Parkinson’s disease: a spotlight on 14-3-3 proteins |
title_short | Pathways to Parkinson’s disease: a spotlight on 14-3-3 proteins |
title_sort | pathways to parkinson’s disease: a spotlight on 14-3-3 proteins |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455551/ https://www.ncbi.nlm.nih.gov/pubmed/34548498 http://dx.doi.org/10.1038/s41531-021-00230-6 |
work_keys_str_mv | AT giustoe pathwaystoparkinsonsdiseaseaspotlighton1433proteins AT yacoubianta pathwaystoparkinsonsdiseaseaspotlighton1433proteins AT greggioe pathwaystoparkinsonsdiseaseaspotlighton1433proteins AT civierol pathwaystoparkinsonsdiseaseaspotlighton1433proteins |